GB04/3623

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed P. Mahoney

Dated 13 October 2004

Patents Form 1/77

Patents Act 1977
(Rule 16)

The Patent Office

27AUG03 E833065-1 D10002
P01/7700 0.00-0320020.1

THE PATENT OFFICE
WM
2 7 AUG 2003
RECEIVED BY FAX

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference
mwe.3103.uk

2. Patent application number
(The Patent Office will fill in this part)
0320020.1
27 AUG 2003

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*
MW Encap Limited
4 Dunlop Square
Industrial Estate
LIVINGSTONE
EH54 8SB

Patents ADP number *(if you know it)*
7027261002

If the applicant is a corporate body, give the country/state of its incorporation
United Kingdom

4. Title of the invention
Improved formulation for providing an enteric coating material

5. Name of your agent *(if you have one)*

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*
Kennedys Patent Agency Limited
Floor 5, Queens House
29 St Vincent Place
GLASGOW
G1 2DT

Patents ADP number *(if you know it)*
80582400002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))
YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	
Description	9
Claim(s)	
Abstract	
Drawing(s)	

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	
Request for preliminary examination and search *(Patents Form 9/77)*	
Request for substantive examination *(Patents Form 10/77)*	
Any other documents *(please specify)*	

11. I/We request the grant of a patent on the basis of this application.

Signature Kennedys

Date 27 August 2003

12. Name and daytime telephone number of person to contact in the United Kingdom CLAIRE RUTHERFORD

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.

IMPROVED FORMULATION FOR PROVIDING AN ENTERIC COATING MATERIAL

The present invention relates to a formulation for providing an enteric coating material and in particular relates to such a material made up of food use approved materials.

In many cases it is a requirement of pharmaceutical and neutraceutical dosage units that they are able to pass through the stomach intact and only release their contents further down the GI Tract. This is necessary when a particular ingredient (or ingredients) of the dosage unit is unstable in the strongly acidic environment of the stomach and where the ingredient or ingredients are intended for release in the slightly alkaline conditions of the GI Tract beyond the stomach.

The prior art shows many cases where pharmaceutical dosage units achieve the abovementioned requirement using an enteric coating. Enteric coating materials are material types that are acid resistant, protecting and preventing the dosage unit from a releasing of the

contents into the stomach. However, these coatings dissolve or disintegrate in the neutral or mildly alkaline conditions that are encountered beyond the stomach. In the pharmaceutical industry enteric coatings are widely used, with a wide choice of enteric materials such as hydroxypropyl methylcellulose phthalate (HPMCP), methacrylic acid/methyl methacrylate copolymers (for example Eudragit ™ materials), cellulose acetate phthalate (CAP) and polyvinyl acetate phthalate (PVAP). All of these enteric materials have been developed over a considerable period to provide a wide range of organic solvent soluble materials or aqueous dispersions which have both excellent coating and enteric properties. However, manufacturers have had to invest heavily to gain approval for the use of their materials in the pharmaceutical industry and rigorous testing of the materials has been required. Although, all of these products have been through this pharmaceutical approval route, they have not been considered as viable propositions for companies to devote similar significant resources to gain approval for use in the food industry. Therefore, although these materials are appropriate enteric materials they are not approved for food use and cannot legally be used to enteric coat non-pharmaceutical dosage units. It can be seen that there would be many cases when it would be useful to provide enteric coatings on items that are non-pharmaceutical dosage units, for example for certain health foods etc.

There are in fact very few materials that are both approved for food use and have been suggested or used as enteric coatings. One possible material that has been suggested is Shellac. Shellac is an exudate of the lac

insect and is a natural material that is insoluble in water but soluble in organic solvents including ethanol. It has been used as a sealing coat on tablet cores, as a food glaze and also as a type of enteric coating. As Shellac is insoluble in acidic conditions but soluble at higher pH levels it would appear to be suitable as an enteric coating material. However, reference texts describe that, in practice, delayed disintegration and delayed drug release occurs *in vivo* as the Shellac coat is not soluble in the upper intestine. Laboratory trials in this case have now shown that Shellac does not behave in a typical enteric coating manner and instead behaves more like an erodible coating, dissolving as a function of time rather than of pH.

Traditionally, Shellac coats have been sprayed from an organic solution, a disadvantage in terms of solution cost and environmental protection cost. It is possible to spray Shellac from an aqueous solution after forming the Shellac into a water soluble alkali salt, and aqueous Shellac salt solutions are commercially available. These commercially available solutions form films that dissolve in neutral or mildly alkaline conditions and appear, at first consideration, to overcome the alkaline insolubility problem of Shellac sprayed from organic solution. However, unfortunately these films react rapidly in acid to revert to the free acid Shellac and, when ingested as a film of a dosage unit, the acidic conditions in the stomach restore the film to Shellac and restore the insolubility problem. Shellac films sprayed as Shellac or as Shellac salts perform similarly and do not resist acid (0.1 H HCl for two hours) then rapidly (within one hour) releases the contents of the dosage

unit in neutral or mildly alkaline conditions in the manner of an enteric coat. Shellac films can be produced that disintegrate between two and three hours and would appear to meet the above requirements. However Shellac films are relatively insensitive to pH and, as described above, disintegrate between two and three hours regardless of the solution acidity or alkalinity and instead behave as erodible films which dissolve as a function of time.

Another material that is approved for food use and has been suggested or used as an enteric coating material is Zein. Zein is a prolamine obtained from corn and is used as a tablet binder or tablet coating agent. It has in the past been used as an enteric coating material. It is insoluble in water and most of the common organic solvents including both acetone and ethanol. It can be dissolved and sprayed as a film from propylene glycol/water solutions but due to the high propylene glycol content (typically over 65%) and high boiling point of propylene glycol its use suffers from technical, solution cost and environmental consideration problems.

Zein coats form a very weak film in acid which, in tests, fail to resist 0.1 N HCl for two hours. The coating does not dissolve in neutral or mildly alkaline conditions and therefore does not perform as a satisfactory enteric coating material. It again has been suggested that the Zein coat is digested rather than dissolves in the intestine, which is a rather unusual, and non-enteric, release mechanism.

It can be seen that it would be beneficial to provide an enteric coating material that overcomes the problems of the prior art.

It is an object of the present invention to provide an enteric coating material.

According to a first aspect of the present invention there is provided an enteric coating formulation comprising shellac and sodium alginate.

Preferably the Shellac is in aqueous form.

Preferably the formulation is edible.

Most preferably the formulation comprises materials that are approved for food use.

Optionally, there is 10-90% Shellac in the formulation.

Optionally, there is 10-90% sodium alginate in the formulation.

Preferably, there is equal quantities of Shellac and sodium alginate in the formulation.

Most preferably, the Shellac is in aqueous salt form.

Preferably, the formulation is in the form of a spray solution or a suspension.

Optionally, the formulation can be applied to a dosage unit in the form of a spray.

Optionally, the pH of the formulation may be adjusted to maintain a useable solution / suspension.

Optionally, the pH of any of the components of the formulation may be adjusted to maintain a useable solution / suspension.

Preferably, a low viscosity grade of sodium alginate is used.

Optionally, a plasticiser may be added to the formulation.

According to a second aspect of the present invention there is provided a dosage unit comprising enteric outer film which is itself comprises Shellac and sodium alginate.

According to a third aspect of the present invention there is provided a method for preparing an enteric coating comprising the steps mixing an aqueous solution of an alkali salt of Shellac with an aqueous solution of sodium alginate.

In order to provide a better understanding of the present invention the invention will be described by way of example only and with reference to the following drawing in which Figure 1 shows a cross section of a dosage unit comprising an enteric coating according to the present invention.

Sodium alginate is GRAS listed and recognised as a food additive in Europe. It is used as a stabilising agent, suspending agent, tablet and capsule disintegrant, tablet binder and viscosity increasing agent. However, until now it has never been suggested as an enteric coating material. It is described in the art as being insoluble below pH 3 and slowly soluble in neutral or alkaline solution and forms aqueous solutions.

Neither Shellac, in free acid or alkaline salt form, nor sodium alginate form films that are acid resistant (where an acid is 0.1 N HCl) and dissolve or disintegrate in neutral/mildly alkaline conditions (ie ph 6.8 buffer), ie neither performs the function of an enteric coat.

In the present invention a mixture of Shellac, in the aqueous salt form, and sodium alginate can be mixed together in a formulation to form a film that resists acid but disintegrates in neutral/mildly alkaline conditions. This film has the properties of an enteric film and is entirely composed of food use approved materials. Therefore, it is usable by the food and neutraceutical industry to coat non-pharmaceutical (ie non-licensed) dosage units where an enteric coating may still be of great use.

As a preliminary step Shellac may be formed into a solution of the alkali salt using standard techniques known in the art. An example of such a technique is to heat Shellac in water, with stirring to 50-55°C then, after dissolution of the Shellac and the addition of 10% solution of ammonium hydrogen carbonate, the mixture is heated to 60°C, with stirring for a further 30 minutes.

On cooling the Shellac remains in solution as the alkali salt.

The coating formulation is formed by mixing an aqueous solution of an alkali salt of Shellac with an aqueous solution of sodium alginate. The content of either material may vary from 10% of one to 90% and will still demonstrate enteric properties in the film formed. Most preferably the constituents are present in equal quantities. The pH of the mixture, or either component within the mixture, may be adjusted to maintain a useable solution or suspension.

The aqueous solution of the alkali Shellac salt may be formed from Shellac as part of the preliminary process using methods known in the art.

It is also worth noting that sodium alginate is commercially available as different grades which form solutions of significantly different viscosities. Preferably, in this case, a low viscosity grade of sodium alginate will be used. The preferred viscosity of sodium alginate is 200-300cps, defined as the viscosity of a 3% solution in water with sequestering agent

A plasticiser may be added to the formulation to modify the flexibility of the film formed to suit the dosage requirements. Examples of plasticisers are triethyl citrate, polyethylene glycol, polypropylene glycol and glycerin monostearate. The plasticisers would typically be added in the 5-25% range. The aqueous Shellac/sodium alginate solution or suspension can, at a suitable concentration which is spraying system dependent, be

sprayed using commercial equipment by personnel skilled in the art to form films on dosage units.

It can be seen that the present invention has a number of benefits over the prior art and up until now this combination of materials has not been known to produce a film that has enteric properties and is acceptable for food use. As none of the materials themselves perform in an enteric manner it is somewhat surprising to find that the combination of material produces a film that shows enteric properties, a property possessed by neither of the components.

It should be noted that the embodiments disclosed above are merely exemplary of the invention which may be embodied in many different forms. Therefore, details disclosed herein are not to be interpreted as limiting but merely as a basis for claims and for teaching one skills in the art as to the various uses of the present invention in any appropriate manner.